A carregar...
Bevacizumab for glioblastoma: current indications, surgical implications, and future directions
Initial enthusiasm after promising Phase II trials for treating recurrent glioblastomas with the antiangiogenic drug bevacizumab—a neutralizing antibody targeting vascular endothelial growth factor—was tempered by recent Phase III trials showing no efficacy for treating newly diagnosed glioblastomas...
Na minha lista:
| Publicado no: | Neurosurg Focus |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4839778/ https://ncbi.nlm.nih.gov/pubmed/25581938 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|